FibroGen (FGEN) Competitors $11.31 -0.42 (-3.58%) Closing price 04:00 PM EasternExtended Trading$11.82 +0.50 (+4.47%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock FGEN vs. CRBU, BIOA, BDTX, MDWD, SXTC, CLLS, FTLF, DERM, BHST, and APLTShould you be buying FibroGen stock or one of its competitors? The main competitors of FibroGen include Caribou Biosciences (CRBU), BioAge Labs (BIOA), Black Diamond Therapeutics (BDTX), MediWound (MDWD), China SXT Pharmaceuticals (SXTC), Cellectis (CLLS), FitLife Brands (FTLF), Journey Medical (DERM), BioHarvest Sciences (BHST), and Applied Therapeutics (APLT). These companies are all part of the "pharmaceutical products" industry. FibroGen vs. Its Competitors Caribou Biosciences BioAge Labs Black Diamond Therapeutics MediWound China SXT Pharmaceuticals Cellectis FitLife Brands Journey Medical BioHarvest Sciences Applied Therapeutics Caribou Biosciences (NASDAQ:CRBU) and FibroGen (NASDAQ:FGEN) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, institutional ownership, risk, earnings, profitability, media sentiment, valuation and analyst recommendations. Which has more volatility and risk, CRBU or FGEN? Caribou Biosciences has a beta of 2.59, meaning that its stock price is 159% more volatile than the S&P 500. Comparatively, FibroGen has a beta of 0.76, meaning that its stock price is 24% less volatile than the S&P 500. Is CRBU or FGEN more profitable? FibroGen has a net margin of -3.86% compared to Caribou Biosciences' net margin of -1,800.93%. FibroGen's return on equity of 0.00% beat Caribou Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Caribou Biosciences-1,800.93% -62.35% -49.65% FibroGen -3.86%N/A -27.34% Which has better valuation & earnings, CRBU or FGEN? FibroGen has lower revenue, but higher earnings than Caribou Biosciences. FibroGen is trading at a lower price-to-earnings ratio than Caribou Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCaribou Biosciences$9.12M23.89-$149.10M-$1.78-1.31FibroGen$7.35M6.23-$47.58M-$0.38-29.76 Do institutionals & insiders have more ownership in CRBU or FGEN? 77.5% of Caribou Biosciences shares are owned by institutional investors. Comparatively, 72.7% of FibroGen shares are owned by institutional investors. 8.3% of Caribou Biosciences shares are owned by insiders. Comparatively, 3.1% of FibroGen shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Do analysts rate CRBU or FGEN? Caribou Biosciences currently has a consensus price target of $6.67, indicating a potential upside of 184.90%. FibroGen has a consensus price target of $43.00, indicating a potential upside of 280.19%. Given FibroGen's higher possible upside, analysts clearly believe FibroGen is more favorable than Caribou Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Caribou Biosciences 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50FibroGen 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Does the media favor CRBU or FGEN? In the previous week, Caribou Biosciences' average media sentiment score of 0.00 equaled FibroGen'saverage media sentiment score. Company Overall Sentiment Caribou Biosciences Neutral FibroGen Neutral SummaryCaribou Biosciences beats FibroGen on 8 of the 14 factors compared between the two stocks. Get FibroGen News Delivered to You Automatically Sign up to receive the latest news and ratings for FGEN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding FGEN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart FGEN vs. The Competition Export to ExcelMetricFibroGenMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$47.44M$2.99B$6.15B$10.62BDividend YieldN/A56.38%5.64%4.69%P/E Ratio-29.7624.4085.6627.13Price / Sales6.23527.08527.36205.87Price / CashN/A28.3526.3031.10Price / Book-0.225.3712.926.67Net Income-$47.58M$32.78M$3.30B$276.23M7 Day Performance-8.12%3.90%4.80%3.31%1 Month Performance-6.53%9.99%8.11%10.76%1 Year Performance23.37%-3.12%75.85%33.58% FibroGen Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)FGENFibroGen4.0722 of 5 stars$11.31-3.6%$43.00+280.2%+28.0%$47.44M$7.35M-29.76570CRBUCaribou Biosciences1.9155 of 5 stars$2.30+8.0%$6.67+189.9%+21.4%$198.35M$9.99M-1.29100Gap UpBIOABioAge Labs0.2826 of 5 stars$5.45+0.6%N/AN/A$194.31MN/A0.00N/ABDTXBlack Diamond Therapeutics3.5392 of 5 stars$3.73+9.7%$11.00+194.9%+3.7%$193.58MN/A16.2290Positive NewsMDWDMediWound1.5445 of 5 stars$17.97+0.4%$32.25+79.5%+2.8%$193.35M$20.22M-6.8180SXTCChina SXT Pharmaceuticals0.5403 of 5 stars$1.62-0.6%N/A-71.2%$189.12M$1.74M0.0090Gap DownCLLSCellectis1.4818 of 5 stars$2.84-15.5%$4.00+40.8%+84.8%$186.76M$49.22M-3.46290Positive NewsGap DownHigh Trading VolumeFTLFFitLife Brands3.8517 of 5 stars$19.91+0.2%$23.00+15.5%+23.1%$186.70M$64.47M23.7020DERMJourney Medical1.4999 of 5 stars$7.10+0.6%$12.17+71.4%+12.3%$185.75M$56.13M-18.6890BHSTBioHarvest SciencesN/A$9.96-8.5%$13.67+37.2%N/A$178.87M$30.19M-14.23N/AGap UpAPLTApplied Therapeutics3.6866 of 5 stars$0.61-50.7%$4.13+574.1%-87.0%$178.57M$460K-1.3630High Trading Volume Related Companies and Tools Related Companies Caribou Biosciences Competitors BioAge Labs Competitors Black Diamond Therapeutics Competitors MediWound Competitors China SXT Pharmaceuticals Competitors Cellectis Competitors FitLife Brands Competitors Journey Medical Competitors BioHarvest Sciences Competitors Applied Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:FGEN) was last updated on 10/6/2025 by MarketBeat.com Staff From Our PartnersStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | SponsoredIs This Warren’s Buffett’s #1 AI Investment?Did you know that Warren Buffett is investing in what Jeff Brown believes will be the next generation of artif...Brownstone Research | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredIs Nvidia about to Trigger Another 150X Opportunity?Nvidia gave investors a chance to make more than 150 times their money with its AI chips, known as graphics pr...InvestorPlace | SponsoredThe $20 stock that could make silicon chips obsolete$2 TRILLION Quantum Gold Rush While everyone fights over expensive AI stocks... McKinsey just revealed the ...The Oxford Club | SponsoredWall Street legend: “Sell this A.I. stock now”Whats next after AI? Hidden AI. "Hidden AI" could soon be the biggest investment trend of 2025.Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding FibroGen, Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share FibroGen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
